All partnering requests
See more requests
Platform technologies for delivery of anti-fibrotic agents to intestinal cells (Europe/UK)
- Background
- What we're looking for
- What we can offer you
- Who we are
- Q&A
Have questions about this request?
Get them answered by the team at Takeda.
Background
Under our purpose “Better Health for People, Brighter Future for the World”, Takeda actively engages in diverse open innovation initiatives to advance patient-focused scientific breakthroughs.
We are currently seeking platform technologies to address unmet medical needs in the Gastrointestinal (GI) therapeutic area. We are specifically interested in partnering with academia and startups across Europe and the UK.
What we're looking for
We are seeking platform technologies that allow for selective delivery of anti-fibrotic agents (e.g. proteins, small molecules, oligos) to activated fibroblasts and macrophages within the fibrotic intestinal tissue of fibrostenotic Crohn’s disease. Approaches that avoid accumulation in other organs are highly desirable.
Our must-have requirements are:
- The researcher belongs to an academic institution or startup in Europe or the UK (If you are interested in participating but are not based in this region, please record your interest in this form.)
- The proposed project can be completed at a cost that is economically feasible within a 1 year timeline
- The proposed project is based on highly differentiated approaches/concepts that comes with an opportunity to develop IP on novel therapeutics in the GI therapeutic area
What we can offer you
Eligible partnership models:
Sponsored research
Benefits:
Sponsored Research
Funding is available up to €50,000 over 1 year for construction and validation of novel platform technologies toward pharmaceutical application in GI disease.Expertise
Takeda may provide chemical, biologic, imaging, or clinical expertise as needed.Who we are
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.
Learn moreReviewers
YU
Yoji Ueda
Associate Director
JB
John Ballew
Takeda Academic Innovation
SC
Suzanne Collins
Sr. Director
Q&A with Takeda
The Q&A is now closed.
Sort by:
Most upvoted
Q.
We are a startup based in India and have a platform technology for delivery to macrophages, which we are validating for antimicrobial applications, and would like to apply. Requesting clarification on eligibility
ND
July 6, 2023
3
A.
We appreciate your interest in this RFP. However, since our primary focus is on EU/UK at this time, we are sorry but you are ineligible to apply. We will consider including other regions in the future RFPs.
YU
Yoji Ueda, Associate Director, Takeda
July 11, 2023
Is this response helpful?
1
0
Q.
Dear A. Dir.: We are involved in the synthesis of inhibitors of the development of the virus responsible of the hepatitis C (since 2008). Please, is this research line eligible in your call? Thank you very much. Regards
1
A.
Thank you for your interest to our RFP. However, your suggested research topic (Hepatitis C) is not our current focus, thus it is unlikely fit this RFP.
YU
Yoji Ueda, Associate Director, Takeda
August 25, 2023
Is this response helpful?
1
0
Q.
We are an academic research team with 30 research papers in design of synthetic and natural small molecules. Are we eligible to apply?
For more details please visit http://vidyaniranjan.co.in/
1
A.
We appreciate your interest in this RFP. However, our primary focus is on EU/UK at this time.
YU
Yoji Ueda, Associate Director, Takeda
July 11, 2023
Is this response helpful?
0
0
Q.
We make a low-cost, 3D graphene foam bioscaffold that is biocompatible and biodegradable. We would gladly provide you with the scaffold material for your researchers to use if this was of any interest.
GE
September 6, 2023
1
A.
Thank you for your interest to our RFP. However, your technology appear to be outside of the scope of this RFP.
YU
Yoji Ueda, Associate Director, Takeda
September 7, 2023
Is this response helpful?
0
0
A.
Thank you for your interest to our RFP. However, your technology appear to be outside of the scope of this RFP.
YU
Yoji Ueda, Associate Director, Takeda
September 7, 2023
Is this response helpful?
1
0
Q.
We are a research group specialized in drug delivery and 3D printing. We have developed colon-specific DDS transporting from small molecules to nanoparticles. Does it corresponds to the profile you are looking for?
1
Q.
My research team is working on polymer micro- and nanocarriers for the colon delivery of both drug compounds and nutraceutical ingredients (with food grade polymers). Could such platforms be interesting for your project?
RP
September 7, 2023
1
Q.
We work on VLPs delivering Prime Editing (PE) allowing and safe genome rewriting. Crohn-disease associated mutations (for ex T300A) may be targeted. Is this of interest?
1
A.
Thank you for your interest in our RFP. Yes, your technology appear to fit within the scope of this RFP. If you are interested in to apply, please do so asap.
YU
Yoji Ueda, Associate Director, Takeda
September 4, 2023
Is this response helpful?
0
0
Sign up to access the full partnering request.
View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.Already have an account? Sign in
Share partnering request
Complete
Refine recommendations
Is this request relevant to you?
Eligible partners
Academic researchersStartups
Seeking partners focused on
Medicinal ChemistryMolecular BiologyPharmacologyBiotechnology
Other recommended requests
NEW
Showcase solutions to industry
Don’t see a matching request for your technology, product, or service? List it and reach thousands of R&D decision-makers.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.